283 related articles for article (PubMed ID: 3676778)
1. Effects of calcium antagonists on muscarinic receptor subtypes in the rat brain.
Katayama S; Kito S; Miyoshi R; Matsubayashi H
Brain Res; 1987 Sep; 422(1):168-71. PubMed ID: 3676778
[TBL] [Abstract][Full Text] [Related]
2. Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex.
Adem A; Sabbagh M; Nordberg A
J Neural Transm; 1988; 72(1):11-8. PubMed ID: 3379385
[TBL] [Abstract][Full Text] [Related]
3. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
4. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
5. Effects of Ca2+ channel ligands on [3H]QNB binding at m1 and m3 muscarinic receptors.
Kwon YW; Triggle DJ
Gen Pharmacol; 1991; 22(2):267-70. PubMed ID: 2055419
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
7. Differential interactions of muscarinic drugs with binding sites of [3H]pirenzepine and [3H]quinuclidinyl benzilate in rat brain tissue.
Tonnaer JA; van Vugt MA; de Boer T; de Graaf JS
Life Sci; 1987 May; 40(20):1981-7. PubMed ID: 3573989
[TBL] [Abstract][Full Text] [Related]
8. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
9. Biochemical characteristics of muscarinic cholinoreceptors in swine tracheal smooth muscle.
Yang CM; Farley JM; Dwyer TM
J Auton Pharmacol; 1986 Mar; 6(1):15-24. PubMed ID: 3957950
[TBL] [Abstract][Full Text] [Related]
10. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
11. Potency ratio for the inhibition of 3H-QNB and 3H-cis-methyldioxolane binding predicts agonist or antagonist activity on muscarinic receptors.
Moret C; Pastrie I; Briley M
Methods Find Exp Clin Pharmacol; 1988 Oct; 10(10):619-21. PubMed ID: 3236936
[TBL] [Abstract][Full Text] [Related]
12. Effects of Pro-Leu-Gly-NH2 and cyclo (Leu-Gly) on the binding of 3H-quinuclidinyl benzilate to striatal cholinergic muscarinic receptors.
Das S; Matwyshyn GA; Bhargava HN
Peptides; 1986; 7(1):21-5. PubMed ID: 2872660
[TBL] [Abstract][Full Text] [Related]
13. Cholinergic innervation and topographical organization of muscarinic binding sites in rat brain: a comparative autoradiographic study.
Tonnaer JA; Ernste BH; Wester J; Kelder K
J Chem Neuroanat; 1988; 1(2):95-110. PubMed ID: 3267343
[TBL] [Abstract][Full Text] [Related]
14. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
15. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors.
Thayer SA; Welcome M; Chhabra A; Fairhurst AS
Biochem Pharmacol; 1985 Jan; 34(2):175-80. PubMed ID: 2981533
[TBL] [Abstract][Full Text] [Related]
16. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Ca2(+)-antagonists nifedipine, verapamil, flunarizine and of the calmodulin antagonist trifluoperazine on muscarinic cholinergic receptors in rat cerebral cortex.
Popova J; Staneva-Stoytcheva D; Mutafova V
Gen Pharmacol; 1990; 21(3):317-9. PubMed ID: 2341018
[TBL] [Abstract][Full Text] [Related]
18. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
19. [3H]AF-DX 116 labels subsets of muscarinic cholinergic receptors in rat brain and heart.
Wang JX; Roeske WR; Gulya K; Wang W; Yamamura HI
Life Sci; 1987 Oct; 41(14):1751-60. PubMed ID: 3657382
[TBL] [Abstract][Full Text] [Related]
20. Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.
Ehlert FJ; Tran LP
J Pharmacol Exp Ther; 1990 Dec; 255(3):1148-57. PubMed ID: 2262898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
